Henry Showell worked at Pfizer Central Research in Groton, CT for 20 years (1981 – 2001) where his laboratory was involved in Arthritis and Allergy/Immunology drug discovery research programs. During that period Henry’s lab contributed to the discovery of multiple novel compounds that entered clinical development. Henry was also a member of multidisciplinary clinical development teams that helped coordinate the advancement of compounds during early phases of clinical development. In his latter years at Pfizer, Henry was a founder member of the DrugPfinder Team at their Cambridge, MA facility. in this role Henry helped establish and manage multiple research collaborations between Pfizer Global Therapeutic Area Teams and academic laboratories in the US, Europe and Asia. Prior to joining Pfizer, Henry held an appointment (1970-1981) In the Department of Pathology at U.Conn Health Center (UCHC) in Farmington, CT. At UCHC Henry worked with Elmer Becker, a renowned Immunologist, where they made several seminal observations on mechanisms of leukocyte chemotaxis in inflammatory diseases that resulted in multiple publications in top tier journals. Henry’s first research experience was at Oxford University in the laboratory of Alan Woodin at the Sir William Dunn School of Pathology (1963 -1970) where the research goal was to delineate the mechanisms of leukocyte toxicity of Staphylococcal Leukocidin. Since retiring from Pfizer Henry has served as an ad hoc external adviser to multiple pharmaceutical and biotechnology companies and research foundations. Henry currently serves on the External Advisory Board of the Program in Innovative Therapeutics for Connecticut’s Health.